
|Videos|June 30, 2016
Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma
Author(s)Maria-Victoria Mateos, MD, PhD
Advertisement
Maria-Victoria Mateos, consultant physician, hematology department, Hospital Universitario de Salamanca, MD, PhD, discusses the TOURMALINE-MM1 trial in multiple myeloma.
The phase III trial investigated the impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) compared to placebo plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
The IRd combination resulted in a significant improvement in progression free survival (PFS) compated to the control arm, says Mateos.
The benefit was sustained across different groups of patients regardless of prior lines of therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5



































